literature

HIV mutation literature information.

Prevalence of primary and secondary resistant mutations to antiretroviral drug in a population of Puerto Rican infected with HIV.

PMID: 12572241 2002 Puerto Rico health sciences journal

Abstract: Mutation frequencies to the NRTI ranged in appearance from as high as 54% (i.e., M184V) in the studied subjects to a low of less than 5% (i.e., M184I and V75T).

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.

PMID: 11316991 2001 AIDS (London, England)

Abstract: Lamivudine elicited the acquisition of the M184I mutation.

Abstract: Phenotypic resistance to all nucleoside-analog reverse transcriptase inhibitors (NRTIs) was increased when M184I was added to the multi-nucleoside resistance background in the absence of NNRTI-resistance mutations.

Abstract: The addition of the M184I mutation to the NNRTI-multi-nucleoside resistance set abolished this antagonizing effect for didanosine, zalcitabine and lamivudine, but further potentiated the phenotypic reversal for zidovudine and stavudine.

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations.

PMID: 11536226 2001 Journal of medical virology

Abstract: The least fit viruses were associated with the RT mutation M184I/V (11.6% less fit) and the PR mutations D30N (12.4% less fit) and M46I/L (21% less fit).

Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.

PMID: 10777142 2000 AIDS research and human retroviruses

Abstract: Lamivudine plus GW420867X selected for the 3TC-specific M184I mutation and a number of NNRTI-characteristic mutations (i.e., V106A, V108I, and Y188H).

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection.

PMID: 10864635 2000 Journal of virology

Abstract: From analysis of the frequency of M184I and M184V mutants determined at multiple time points in seven individuals during lamivudine therapy, we estimated the fitness advantage of M184V over M184I during therapy to be approximately 23% on average.

Abstract: Human immunodeficiency virus type 1 (HIV-1) rapidly develops resistance to lamivudine during monotherapy, typically resulting in the appearance at position 184 in reverse transcriptase (RT) of isoleucine instead of the wild-type methionine (M184I) early in therapy, which is later replaced by valine (M184V).

Abstract: We have found that the differences between individuals in the rate of evolution of lamivudine resistance arise due to genetic d

The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.

PMID: 10873473 2000 Journal of molecular biology

Abstract: Both of the mutations, M184I and M184V, provide very high levels of resistance in vivo; purified HIV-1 RT carrying M184V and M184I also shows resistance to 3TCTP and FTCTP in in vitro polymerase assays.

Abstract: Structural studies suggest that the mechanism of resistance of HIV-1 RTs carrying the M184V or M184I mutation involves steric hindrance, which could either completely block the binding of 3TCTP and FTCTP or allow binding of these nucleoside triphosphate molecules but only in a configuration that would prevent incorporation.

Abstract: The initial change is usually to M184I; this virus is rapidly replaced by a varia

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee.

PMID: 10894274 2000 AIDS (London, England)

Abstract: Ten of the thirteen patients had a 44-52 week HIV viral load > 1000 copies/ml, all of whom also had HIV reverse transcriptase M184V or M184I mutations.

Isolation and characterization of simian immunodeficiency virus variants that are resistant to nonnucleoside reverse transcriptase inhibitors.

PMID: 11205100 2000 Archives of virology

Abstract: These amino acids are highly conserved in HIV-1, HIV-2, SIVmac and SIVagm, and the M184I (M185I in SIVagm) substitution was observed in 3TC-resistant HIV-1 and SIVmac.

Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.

PMID: 10432679 1999 Nucleosides & nucleotides

Abstract: Cloning and sequencing of the RT genes of the selected viruses identified two mutations, M184I for (+) dOTC and M184V for (-) dOTFC.

Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.

PMID: 10449287 1999 AIDS (London, England)

Abstract: Met184Val and Met184Ile, result in an increase in polymerase fidelity of the enzyme as measured in biochemical assays; however, the effect of such changes on the fidelity during viral replication is largely unknown.

Abstract: CONCLUSION: This study demonstrates that the Met184Val and Met184Ile mutations in the HIV-1 reverse transcriptase enzyme do not significantly affect the evolutionary potential of the corresponding viruses.

Abstract: DESIGN AND METHOD: In vitro selection experiments with either wild-type or lamivudine-resistant viruses (Met184Val and Met184Ile) were performed using a protease inhibitor as the selective drug.

Browser Board

Co-occurred Entities

Filtrator